Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Kills ISO Voluntary Audit Program As MDSAP Efforts Accelerate

This article was originally published in The Gray Sheet

Executive Summary

The agency has terminated a 2012-launched ISO 13485 voluntary audit program, which gave companies the chance for a one-year reprieve from an FDA inspection, to put all attention on the global Medical Device Single Audit Program.

You may also be interested in...

FDA Report: MDSAP Single-Audit Pilot Challenged By Device-Maker Recruitment

A mid-pilot program update from the Medical Device Single Audit Program shows the number of interested manufacturers spiked sharply in July, but is still a far cry from the end-of-2016 target of 330 participating companies. However, the pilot is meeting auditor recruitment and training goals.

10 Things You Should Know About The Medical Device Single-Audit Pilot

After a long build up, four international regulatory authorities officially rolled out the Medical Device Single Audit Program pilot this month. Here are 10 things companies should know about the program.

FDA’s ISO Audit Program Chugs Along; May Be Absorbed By IMDRF Single-Audit Initiative

Thirty manufacturers have used FDA’s ISO 13485 voluntary audit program since the two-year pilot began last June, freeing up scarce agency inspectional resources to be used elsewhere. However, it will likely be eventually absorbed by a pilot Medical Device Single Audit Program currently under development by the International Medical Device Regulators Forum.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts